SARS-CoV-2 showed how measures against airborne pathogens are critical in clinical environments. Bacteria make no exception. Healthcare-associated or Hospital-Acquired Infections (HAIs) represent one of the major concerns in the Western world, impairing the clinical outcome of up to 15% of all hospitalized patients [1]. Every year in the European community about 3.2 million patients acquire a HAI, and 37,000 die as a direct consequence of HAI, and the presence of Multi-Drug Resistant (MDR) bacteria is a growing concern [1,2].